None listed
Conditions
Brief summary
- This clinical trial aims at describing the clinical features of COVID-19, the response to treatment, as well as pathogen replication, excretion and evolution within the host, determinants of severity and transmission using high-throughput sequencing of pathogen genomes obtained from respiratory tract, blood and stool. - Characterise the host responses to infection and therapy over time, including innate and acquired immune responses, circulating levels of immune signalling molecules and gene expression profiling in peripheral blood - Identify host genetic variants associated with disease progression or severity - Understand transmissibility and probabilities of different clinical outcomes following exposure and infection
Interventions
Exposure to COVID-19.
Participant involvement is required, including but not limited to extra nasopharyngeal swabs, blood draws, as well as possible surveys (local site intervention is bound to ISARIC protocol).
There may be follow-up after discharge, at 3 and 6 month timepoints (protocol is evolving).
Sponsors
South Metropolitan Health Service
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Suspected or proven novel Coronavirus (nCoV) infection as main reason for admission or presentation to hospital or clinic.
Exclusion criteria
Confirmed diagnosis of a pathogen unrelated to the objectives of this study and no indication or likelihood of co-infection with a relevant pathogen Refusal by participant, parent, or appropriate representative. Any other reason, as determined by the Lead Investigator or treating clinician, that the patient should not be included in the study, in-line with ICH GCP (E6 R2) requirements and the Australian Code for Responsible Conduct of Research (2018).
Outcome results
None listed